LOXO-292 (Synonyms: selpercatinib) |
| Catalog No.GC19547 |
LOXO-292 (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. LOXO-292 has anticancer activity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2152628-33-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
LOXO-292 (Selpercatinib, LOXO 292, LOXO292) is a potent, selective, orally available RET kinase inhibitor with potential antineoplastic activity; displays >100-fold selectivity versus important off-targets; shows anti-tumor activty in the brain and periphery in RET-dependent tumor models in vivo.Lung Cancer
Reference:
[1]. Subbiah V, et al. Ann Oncol. 2018 Aug 1;29(8):1869-1876.
[2]. Cancer Discov. 2018 Aug;8(8):904-905.
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *